content_image/63525.jpg content_image/63523.jpg content_image/63521.jpg content_image/63519.jpg
Assuming the change in accounting for sales in Japan was effective as of January 1 , 1999 , excluding the impact of foreign currency exchange rate fluctuations and assuming the sales of the mechanical cardiac assist product line, the perfusion product 

<img src='content_image/63525.jpg'>

Cardiac Surgery The Adjusted Net Sales growth in 2001 and 2000 in cardiac surgery products resulted primarily from strong sales growth of pericardial tissue valves and repair products. This increase was partially offset by declines in porcine tissue valve sales as a result of competition and as customers upgraded to pericardial tissue valves. Management expects that its cardiac surgery products will continue to serve as a key driver of Edwards Lifesciences’ sales growth. 

Critical Care The Adjusted Net Sales growth in 2001 and 2000 in critical care products was due primarily to strong sales of advanced technology catheter products and the newer access and hemofiltration product categories, partially offset by the decline in base hemodynamic catheters. Critical care products have been, and are expected to continue to be, significant contributors to Edwards Lifesciences’ total sales. 

Vascular The decline in Adjusted Net Sales for vascular products resulted primarily from the continued shift to less- invasive therapies and non-surgical options, and the wind-down of a distribution contract in France during 2001 . Management continues to see opportunities in peripheral vascular disease 

## Gross Margin 

<img src='content_image/63523.jpg'>

line and the perfusion services business had occurred as of January 1 , 1999 (see “Disposition of Assets and Other Non- Recurring Charges, net”), net sales by product line would have changed as follows (“Adjusted Net Sales”): 

treatment and intends to build on the Company’s strong base franchise by developing and marketing minimally invasive therapies such as its Lifepath AAA Endovascular Graft System. In September 2001 , the Company received approval to re-enter the market in Europe with its Lifepath AAA Endovascular Graft System, and in October 2001 received approval from the Food and Drug Administration to restart clinical studies for the same product in the United States. 

Perfusion The Adjusted Net Sales decreases for perfusion were due primarily to a reduction in 2001 of products sales to Jostra AG (see “Disposition of Assets and Other Non- Recurring Charges, net”) and a continually increasing number of “beating-heart” coronary artery bypass surgeries in Western Europe, which reduced the need for perfusion services. 

Other Other sales include miscellaneous pharmaceutical and distributed products. The decline in Adjusted Net Sales in 2000 was due primarily to the termination of certain distributed products at the end of 1999 and the $ 5 million sale of a patent during 1999 . 

Assuming the change in accounting in Japan was effective as of January 1 , 1999 , and assuming the sales of the mechanical cardiac assist product line, the perfusion product line and the perfusion services business had each occurred on January 1 , 1999 (see “Disposition of Assets and Other Non-Recurring Charges, net”), the gross profit percentage (“Adjusted Percentage”) would have been 57 % in 2001 , 54 % in 2000 and 54 % in 1999 . 

## Selling, General and Administrative (“SG&A”) Expenses 

<img src='content_image/63521.jpg'>

Assuming the change in accounting in Japan was effective as of January 1 , 1999 , and assuming the sales of the mechanical cardiac assist product line, the perfusion product line and the perfusion services business had each occurred on January 1 , 1999 (see “Disposition of Assets and Other Non-Recurring Charges, net”), SG & A expenses as a percentage of net sales (“Adjusted Percentage”) would have been 31 % in 2001 , 29 % in 2000 and 24 % in 1999 . 

## Research and Development Expenses 

<img src='content_image/63519.jpg'>

Assuming the change in accounting in Japan was effective as of January 1 , 1999 , and assuming the sales of the mechanical cardiac assist product line, the perfusion product line and the perfusion services business had each occurred on January 1 , 1999 (see “Disposition of Assets and Other Non-Recurring Charges, net”), research and development expenses as a percentage of net sales (“Adjusted Percentage”) would have been 8.7 % in 2001 , 7.6 % in 2000 and 6.6 % in 1999 . 

The Adjusted Percentage increases in research and development expenses for 2001 and 2000 reflect Edwards Lifesciences’ commitment to ongoing research and development to deliver clinically advanced new products, to enhance the effectiveness, ease of use, safety and reliability of its current leading products and to expand the applications of its products 

The Adjusted Percentage increase in the gross profit percentage for 2001 was due primarily to increased sales of higher-margin cardiac surgery products. The Adjusted Percentage for 2000 was also favorably impacted by increased sales of higher-margin cardiac surgery products, offset by an unfavorable impact of foreign currency exchange rate fluctuations. 

The Adjusted Percentage increases in SG & A expenses as a percentage of net sales for 2001 and 2000 were due primarily to additional personnel costs and expenses associated with the Company’s operation as an independent company commencing April 1 , 2000 . Additionally, in 2000 , the Company established a $ 9.5 million reserve for litigation, property taxes and un- collectable receivables. 

as appropriate. In furtherance of this commitment, the Company expects to increase in 2002 its research and development expenses by 20 % from 2001 . 

Goodwill Amortization Goodwill amortization was $ 19 million, $ 29 million and $ 34 million in 2001 , 2000 and 1999 , respectively. The reduction in goodwill amortization for the years 2001 and 2000 resulted primarily from (a) the sale of the perfusion services business in the United States and the disposition of the related goodwill effective June 30 , 2001 , and (b) the write- down of goodwill effective June 30 , 2000 related to the sale of the Company’s line of perfusion products in the United States and Western Europe (see “Disposition of Assets and Other Non-Recurring Charges, net”). 

